Mayo Clinic in Arizona

Running trials

• Not yet recruiting

  A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)

  NCT07906665· Phase 1· Sachi Bioworks Inc.· Source

• Not yet recruiting

  Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial

  NCT07206589· Mayo Clinic· Source

• Not yet recruiting

  Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial

  NCT07935889· Phase 3· Mayo Clinic· Source

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Johns Hopkins University· Source

• Not yet recruiting

  Strengthening Teen Brain Resilience Using Music Intervention to Improve Radiation Induced Cognitive Decline for Adolescents Undergoing Radiation Therapy for Cancer Treatment

  NCT07729384· Mayo Clinic· Source

• Recruiting

  Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors

  NCT07856394· Mayo Clinic· Source

• Recruiting

  Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

  NCT07708961· Phase 2· Mayo Clinic· Source

• Recruiting

  Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  NCT07805954· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

  NCT07498426· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Biologics in Chronic Rhinosinusitis With Nasal Polyposis

  NCT06824649· Phase 4· Medical University of South Carolina· Source

• Recruiting

  A Phase 1 Study of the Safety and Tolerability of CTX-10726

  NCT07419841· Phase 1· Compass Therapeutics· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

  NCT07428616· Phase 2· Exelixis· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07450859· Phase 2· BicycleTx Limited· Source

• Recruiting

  A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  NCT07277413· Phase 1· IDEAYA Biosciences· Source

• Enrolling by invitation

  Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

  NCT07594496· Mayo Clinic· Source

• Recruiting

  A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Pfizer· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· CellCentric Ltd.· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Cartography Biosciences· Source

• Recruiting

  Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms

  NCT04661215· Johns Hopkins Bloomberg School of Public Health· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Lyell Immunopharma, Inc.· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change

  NCT07110337· Epiminder America, Inc.· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

  NCT07110454· Epiminder America, Inc.· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

  NCT07226856· Phase 2· Mayo Clinic· Source

• Recruiting

  Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

  NCT07188532· Mayo Clinic· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Enrolling by invitation

  Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma

  NCT07212491· Mayo Clinic· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

  NCT07170917· Phase 2· Sanofi· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

  NCT06525766· Phase 2· Mayo Clinic· Source

• Recruiting

  Q702 for the Treatment of Patients With Hematologic Malignancies

  NCT06712810· Phase 1· Mayo Clinic· Source

• Recruiting

  Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

  NCT07025369· Phase 2· Mayo Clinic· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· BioNTech SE· Source

• Active, not recruiting

  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

  NCT06985147· Phase 2· Disc Medicine, Inc· Source

• Recruiting

  Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

  NCT07091864· Mayo Clinic· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

  NCT07100990· Phase 3· Mayo Clinic· Source

• Recruiting

  Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

  NCT06972056· Phase 4· Mayo Clinic· Source

• Recruiting

  Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

  NCT06464926· Enterra Medical, Inc.· Source

• Recruiting

  REgulatory T Cell Therapy to Achieve Immunosuppression REduction

  NCT06552169· Phase 2· Singulera Therapeutics Inc.· Source

• Recruiting

  Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

  NCT06668493· Phase 1/2· Ferring Pharmaceuticals· Source

• Recruiting

  App-Based Optimization of Long-Term CPAP Adherence and Quality of Life

  NCT06381115· Mayo Clinic· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

  NCT06635980· Phase 2· Mayo Clinic· Source

Showing 50 of 255.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer9 recruiting
• Multiple myeloma9 recruiting
• Colorectal cancer8 recruiting
• Pancreatic cancer8 recruiting
• Childhood cancers7 recruiting
• Prostate cancer7 recruiting
• Bladder cancer6 recruiting
• Gastric and oesophageal cancer6 recruiting
• Sarcoma6 recruiting
• Acute myeloid leukaemia5 recruiting
• Kidney cancer5 recruiting
• Myelodysplastic syndromes5 recruiting
• Ovarian cancer5 recruiting
• Endometrial cancer4 recruiting
• Glioblastoma4 recruiting
• Liver and biliary tract cancer4 recruiting
• Melanoma4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Crohn's disease3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Epilepsy3 recruiting
• Follicular lymphoma3 recruiting
• Metastatic breast cancer3 recruiting
• Migraine3 recruiting
• Neuroendocrine tumours3 recruiting
• Ulcerative colitis3 recruiting
• Alzheimer disease2 recruiting
• Amyloidosis2 recruiting
• Barrett's oesophagus2 recruiting
• Chronic myeloid leukaemia2 recruiting
• COPD2 recruiting
• Gastroparesis2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• Mesothelioma2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Obesity2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Cannabis use disorder1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic rhinosinusitis with nasal polyps1 recruiting
• Coronary artery disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hidradenitis suppurativa1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Lewy body dementia1 recruiting
• Liver cirrhosis1 recruiting
• Long COVID and ME/CFS1 recruiting
• Mantle cell lymphoma1 recruiting
• Meningioma1 recruiting
• Narcolepsy1 recruiting
• Obstructive sleep apnoea1 recruiting
• Optic neuritis1 recruiting
• Osteoporosis1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Terminated

  Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06790966· Phase 3· PDS Biotechnology Corp.· Source

• Terminated

  Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

  NCT06524739· Phase 3· CSL Behring· Source

• Terminated

  NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

  NCT06420349· Phase 1· Mayo Clinic· Source

• Completed

  Implementation of a Digital Clinic for Alcohol-associated Liver Disease and Alcohol Use Disorder (DALC)

  NCT06319222· Mayo Clinic· Source

• Completed

  Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

  NCT05730712· Phase 2· Mayo Clinic· Source

• Terminated

  CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

  NCT05689021· Phase 2· Mayo Clinic· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Polaris Group· Source

• Completed

  Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)

  NCT06126796· Mayo Clinic· Source

• Completed

  A Study of Deucravacitinib to Treat LPP and FFA

  NCT06091956· Phase 2· Mayo Clinic· Source

• Completed

  A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

  NCT06151717· Mayo Clinic· Source

• Completed

  Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

  NCT06037863· Mayo Clinic· Source

• Terminated

  ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

  NCT06026332· Ferring Pharmaceuticals· Source

• Completed

  Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation Treatment Planning

  NCT05979883· Mayo Clinic· Source

• Completed

  Myositis Interstitial Lung Disease Nintedanib Trial

  NCT05799755· Phase 4· Rohit Aggarwal, MD· Source

• Terminated

  A Study to Evaluate Safety and Effectiveness of G-POEM for Gastroparesis

  NCT04869670· Mayo Clinic· Source

• Completed

  Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

  NCT05557162· Mayo Clinic· Source

• Completed

  Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study

  NCT06063603· Mayo Clinic· Source

• Completed

  A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

  NCT05712356· Phase 2· Lisata Therapeutics, Inc.· Source

• Completed

  Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

  NCT05593328· Phase 2· Cardiff Oncology· Source

• Terminated

  A Study of Remote Electrical Neuromodulation for Acute Procedural Pain

  NCT05730556· Mayo Clinic· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

• Terminated

  Testing Obeticholic Acid for Familial Adenomatous Polyposis

  NCT05223036· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  A Study of TAK-861 in Participants With Narcolepsy Type 2

  NCT05687916· Phase 2· Takeda· Source

• Completed

  GCC Agonist Signal in the Small Intestine

  NCT05107219· Phase 1· University of Wisconsin, Madison· Source

• Completed

  A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

  NCT05376800· Phase 1· Boehringer Ingelheim· Source

• Terminated

  Oral AMXT 1501 Dicaprate in Combination With IV DFMO

  NCT05500508· Phase 1/2· Aminex Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

  NCT05593432· Phase 2· Incyte Corporation· Source

• Completed

  Study of DF9001 in Patients With Advanced Solid Tumors

  NCT05597839· Phase 1/2· Dragonfly Therapeutics· Source

• Terminated

  E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

  NCT05388877· Phase 1· Mayo Clinic· Source

• Completed

  IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

  NCT05372003· Early phase 1· Mayo Clinic· Source

• Completed

  RNS System NAUTILUS Study

  NCT05147571· NeuroPace· Source

• Completed

  A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

  NCT05442047· Phase 2· Novo Nordisk A/S· Source

• Completed

  Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

  NCT05945290· Mayo Clinic· Source

• Completed

  Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

  NCT05854992· Mayo Clinic· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source

• Terminated

  Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

  NCT05288062· Phase 2· Mayo Clinic· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Terminated

  Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  NCT05103904· Phase 2· Emory University· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis

  NCT05160532· Phase 2· Mayo Clinic· Source

• Terminated

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  NCT05242822· Phase 1· Kinnate Biopharma· Source

• Terminated

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Terminated

  Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients with Prostate Cancer

  NCT06016504· Mayo Clinic· Source

• Completed

  Regulation of Muscle Protein Phenotype in Humans With Obesity

  NCT04700800· Mayo Clinic· Source

• Completed

  Development of an EEG Diagnostic for Alzheimer's Disease

  NCT04954183· Mayo Clinic· Source

• Terminated

  Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer

  NCT04805788· Phase 2· Mayo Clinic· Source

• Completed

  Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study

  NCT05053100· Mayo Clinic· Source

• Terminated

  A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

  NCT04577963· Phase 1/2· Hutchmed· Source

Showing 50 of 128.

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation73 works · 1 trial
• Prostate cancer66 works · 30 trials
• Deep vein thrombosis and pulmonary embolism50 works · 2 trials
• Asthma46 works · 0 trials
• Multiple myeloma45 works · 31 trials
• Migraine42 works · 8 trials
• Pancreatic cancer38 works · 13 trials
• Melanoma37 works · 13 trials
• Bladder cancer28 works · 22 trials
• Glioblastoma25 works · 17 trials
• Acute myeloid leukaemia21 works · 10 trials
• Ventricular tachycardia21 works · 0 trials
• Neuroendocrine tumours20 works · 4 trials
• Hypertrophic cardiomyopathy17 works · 0 trials
• Obstructive sleep apnoea16 works · 1 trial
• Aortic stenosis15 works · 0 trials
• Eosinophilic oesophagitis12 works · 0 trials
• Aortic aneurysm11 works · 2 trials
• Chronic lymphocytic leukaemia10 works · 11 trials
• Myeloproliferative neoplasms10 works · 9 trials
• Barrett's oesophagus8 works · 4 trials
• Dermatomyositis and polymyositis (myositis)8 works · 2 trials
• Gastroparesis8 works · 3 trials
• Uterine fibroids7 works · 0 trials
• Narcolepsy7 works · 2 trials
• Follicular lymphoma6 works · 6 trials
• Brain aneurysm6 works · 0 trials
• Fibromyalgia5 works · 0 trials
• Lichen planus5 works · 2 trials
• Haemophagocytic lymphohistiocytosis4 works · 0 trials